Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.42 |
| ▸ | PPARA | Q07869 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4227684 | 0.91 | PPARG (0.43) | PPARGPPARAPTGESSCN9A | |
| SCHEMBL4221843 | 0.91 | PPARG (0.41) | PPARGPPARAPTGESSCN9A | |
| SCHEMBL4216575 | 0.89 | PPARG (0.44) | PPARGPPARAPTGESSCN9A | |
| SCHEMBL3007687 | 0.88 | PPARG (0.45) | PPARGPPARASMN1; SMN2PTGESAKR1C3 | |
| SCHEMBL4226245 | 0.86 | PPARG (0.42) | PPARGPPARAPTGES | |
| SCHEMBL4228390 | 0.84 | PPARG (0.50) | PPARGPPARAPTGES | |
| SCHEMBL4226241 | 0.83 | PPARG (0.44) | PPARGPPARAPTGES | |
| SCHEMBL3010781 | 0.81 | ELANE (0.44) | PPARGPPARASMN1; SMN2 | |
| SCHEMBL4914794 | 0.81 | PTGES (0.46) | PPARGPPARASMN1; SMN2PTGES | |
| SCHEMBL4923368 | 0.80 | PPARG (0.45) | PPARGPPARASMN1; SMN2PTGESAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042949-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042949-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, AREG | PPARG 2457/4885PPARA 3415/4885NPC1 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.